Geometric isomers of radioiodinated L-meta tyrosine, 6-[1-125]iodo-and 4-[1-125]iodo-L-meta-tyrosine (6-1-L-mTyr, 4-I-L-mTyr) were separated by high-performance liq uid chromatography . Both 6-1-and 4-I-L-mTyr had high en ergy-dependent brain accumulation. 6-1-and 4-I-L-mTyr were also metabolically stable and were rapidly excreted through the urine. 6-I-L-mTyr had a predilection for the cerebral aromatic
Alteration in the dopamine biosynthesis has been im plicated in development of neurodegenerative (Tissingh et aI., 1997) and neuropsychiatric diseases and drug abuse (Hornykiewicz, 1982; Volkow and Fowler, 1992) . Development of radiopharmaceuticals that would assess dopaminergic function in vivo is beneficial. Radiophar maceuticals are used to distinguish schizophrenic from normal patients (Dao-Castellana et aI., 1997) . In idio pathic Parkinson's disease, radiopharmaceuticals are used for early detection of disease and to monitor effi cacy of treatments (Tissingh et aI., 1997) . It would not only allow us to develop treatment but also at the same time to directly monitor the result of the management of alterations in the dopamine biosynthesis (Sawle et aI., 1992; Choksi et aI., 1997) .
At present there are two accepted radiopharmaceuti cals for the study of the dopaminergic presynaptic ter minals, 213-carboxymethoxy-313-( 4-[I -123 ]iodophen yl)tropane (I-I3CIT) and 6-[F-18]fluoro-3,4,-dihydroxy-L-amino acid decarboxylase (DOPA decarboxylase), the final enzyme of dopamine biosynthesis. 6-Radioiodinated L-mTyr is a new radiopharmaceutical that can be both useful in assessing cerebral amino acid transport mechanism and quantifying metabolically active DOPA decarboxylase. Key Words: 6-lodo-L-meta-tyrosine-Amino acid transport system DOPA decarboxylase.
L-phenylalanine (6-F-DOPA). I-I3CIT, a cocaine analog, is for single photon emission-computed tomography and has an affinity for dopamine transporters. Because dopa mine transporters are localized in presynaptic terminal, it serves as a marker of dopamine neurons (Neumeyer et aI., 1991; Asenbaum et aI., 1997) .
6-F-DOPA, an analog of L-DOPA, is the only true radiopharmaceutical for presynaptic dopaminergic bio synthesis (Garnett et aI., 1978) . However, 6-F-DOPA is metabolized by catechol-a-methyl transferase to 3-0methyl-6-F-DOPA which complicates the specific-to nonspecific accumulation of radioactivity in the brain (Luxen et aI., 1992) . It can only be used for positron emission tomography, which is not widely available and is expensive to maintain.
So there was a need to develop a new radiopharma ceutical for single photon emission-computed tomogra phy that was easy to prepare and whose uptake pattern was easily interpreted. L-meta-Tyrosine (L-mTyr), also an L-DOPA derivative which is not a substrate of cat echol-a-methyl transferase (De Jesus et aI., 1990) , was selected. It has L-amino acid configuration accounting for amino acid transport and tissue affinity. The phenol moiety provides a site for easy iodination. With the similarity of 3-hydroxy moiety to L-DOPA, L-mTyr re tained its affinity to an aromatic L-amino acid decarbox ylase (DOPA decarboxylase) (Srinivasan and Awapara, 1978) .
In our previous study, the radioiodination of L-mTyr led to the development of radio iodinated L-mTyr (I-L mTyr) which has features that are different from its par ent compound. The characteristics of I-L-mTyr were evaluated. It was found that I-L-mTyr had high cerebral uptake. Its accumulation in the brain was stereospecific and energy dependent. It was resistant to deiodination and was rapidly excreted. This was attributed to its being in the L-form which penetrates the brain more rapidly and in the hydroxy group at 3-position which accounts for its stability. Hence, I-L-mTyr was then endorsed as a single photon emission-computed tomography imaging agent for evaluation of cerebral amino acid transport mechanism (Kawai et aI., 1999) .
The direct radioiodination of L-mTyr resulted in two major geometric isomers, 6-iodo-and 4-iodo-L-meta tyrosine (6-I-L-mTyr, 4-I-L-mTyr). In this study, the two radioiodinated geometric isomers of L-mTyr were sepa rated with high-performance liquid chromatography (HPLC) based on the method of Adam et aI. (1989) . In vitro and in vivo animal studies were carried out to de termine the most suitable isomer for evaluation of cere bral amino acid transport mechanism and the dopami nergic presynaptic biosynthesis. Reagent-grade chemicals were used in this experiment. D,L mTyr was acquired from Sigma (St. Louis, MO, U.S.A.), and separation was done with HPLC using a chiral column (Crown pak CR(-), 4 x 150 mm, Daicel, Tokyo, Japan). [I-125]-NaI was obtained from Amersham (Tokyo, Japan). Radioiodination was performed using the chloramine-T method. Chloramine-T (Aldrich, Milwaukee, WI, U.S.A.) at a concentration of 1.0 x 10-3 mollL in 10 f.1L of 0.05 mollL phosphate buffer (pH 8.5) was added to a mixture of L-or D-mTyr (100 f.1L of 1.0 x 10-3 mollL) and carrier-free [I-125]-NaI (3.7 to 7.4 MBq) in 35 f.1L of 0.4 mollL phosphate buffer (pH 8.5). The resultant solution was allowed to stand for 30 minutes, and sodium metabisulfite (1.0 x 10-3 mollL in 10 f.1L of 0.05 mollL phosphate buffer, pH 8.5) was then added. A geometric isomer separation was then done with HPLC using Nova-Pak C I 8 (3.9 x 300 mm, 0.02 mollL potassium acetate: ethanol = 90: 10, flow rate; 0.5 mLl min, retention time; 6-isomer: 22 to 26 minutes; 4-isomer: 17 to 20 minutes; 1-: 4 to 5 minutes; unlabeled mTyr: 5 to 7 minutes) (Adam et a!., 1989) . The isomeric purity was confirmed with reinjection in the same HPLC condition. The labeling effi ciency and the radiochemical purity were studied by silica gel thin-layer chromatography (TLC, Merck [Darmstadt, Ger many]; Art. 5553) using two solvent systems, methanol to ace tic acid = 100: 1 (Rf value: I-mTyr, 0.5; 1-, 0.8) and methanol to 10% ammonium acetate = 10: 1 (Rf value: I-mTyr, 0.5; 1-, 0.8). Solvent exchange was done with saline for animal experi ments.
As references, 3-[I-125]-L-tyrosine (I-L-Tyr) was prepared using the above mentioned method except the isomeric purifi cation.
In vivo mouse biodistribution and mouse excretion studies Three to nine ddY male mice (6 weeks old) received 0.1 mL saline of radioiodinated tyrosine derivatives (11.1 kBq) via the tail vein (intravenously). The mice were anesthetized with ether and then killed at various time intervals by heart puncture. Organs were then dissected, and their radioactivities were mea sured by a well-type scintillation counter (Aloka [Tokyo, Ja pan]; ARC-300).
Different groups of three to five ddY male mice (6 weeks old) injected with 0.1 mL saline containing the I-mTyr (55.5 kBq) via the tail vein were placed in metabolic cages under feeding conditions. Samples of urine and feces were collected at various time intervals, and their radioactivities were mea sured. Thin-layer chromatography and HPLC analyses of the urine samples were conducted under previously mentioned conditions.
In vitro accumulation studies in rat brain and pancreas
Five Wistar male rats weighing 300 to 350 g were killed by decapitation, and the brain and the pancreas were quickly dis sected. The brain and the pancreas were washed with ice-cold Krebs-Ringer phosphate buffer (pH 7.4) and HEPES buffer (pH 7.4), respectively. Both were sliced with a conventional Stadie Riggs slicer. The slices (each weighing 100 ± 5 mg) were next placed into vials containing 1.9 mL of Krebs-Ringer phosphate buffer or HEPES buffer (pH 7.4), respectively, as their incu bation medium and were preincubated for 10 minutes for tem perature equilibration. Then, 0.1 mL of the buffer containing radioiodinated mTyr (1.85 kBq) was added, and incubation was performed at 37°C for 30 minutes.
Inhibition studies of the membrane-active transport were performed using ouabain inhibition. For the ouabain inhibition study, brain slices were preincubated at 37°C for 10 minutes in medium containing 1.0 x 10-5 mollL ouabain, and the radio active sample was injected and incubated for 30 minutes. For the inhibition studies on the enzyme of the dopamine biosyn thesis, 0.1 mL of 1.0 x 10-3 mollL of 3-hydroxybenzyl hydra zine dihydrochloride (NSD-1015, Aldrich) or 1.0 x 10-3 mollL of 3,4-dihydroxyphenylpropylacetamide (H22/54, Aldrich) was added, and incubation was performed at 37°C for 10 minutes. Solvent exchange was performed, and then 0.1 mL of I-mTyr (1.85 kBq) was added and incubated for 30 minutes.
At the end of the incubation period the medium was re moved, and the slices were washed twice with 2.0 mL of ice cold buffer. The radioactivities of the slices were measured, and the accumulation percentage of the injected dose per gram of slice was then calculated.
In vivo inhibition studies and autoradiography
In a ddY male mouse weighing 30 g, 0.1 mL of 6-I-L-mTyr (670 kBq) was injected intravenously. For the inhibition stud ies, NSD-1015 or H22/54 (50 mg/kg body weight) was intra peritoneally preloaded 30 minutes before intravenous injection of 6-I-L-mTyr. Five minutes later, the mouse was anesthetized and killed. The brain was immediately dissected, washed, placed in an embedding medium and then frozen at -15°C for 24 hours. With a cryostat microtome (Handex, Shiraimatsu), 20 f.1m axial slices were generated from top to bottom. Slices were then air-dried at -15°C for another 24 hours. Contact was made between tissue and the imaging plate (Fuji Photo Film; BAS TR2040, 20 x 40 cm) for at least 24 hours. Images were pro cessed with Bio-Imaging Analyzer (Fuji Photo Film; BAS-2000) . Table 1 . In the brain, there was higher uptake with 4�I-L-mTyr than 6-I-L-mTyr in the early phase. In both I-L-mTyr isomers the highest accu mulations were at 2 minutes after intravenous adminis tration which was then followed by a gradual decline. With 6-I-L-mTyr, retention was noted unlike with 4-I-L mTyr. In Table 2 , rapid clearance of l-mTyr from the blood was also noted compared to 3-I-L-Tyr which is a metabolic intermediate of thyroid hormones that showed rapid enzymatic deiodination (Kawai et aI., 1999) . For both geometric isomers of I-L-mTyr, the uptake in the pancreas was higher than in the liver. 6-I-L-mTyr showed higher uptake in the pancreas than 4-I-L-mTyr (Table 3) .
Three hours after administration, more than 70% and less than 5% of I-L-mTyr was found in the urine and the feces, respectively. The urine analysis by thin-layer chro matography 30 minutes after intravenous administration showed that more than 90% of the radioactivity was attributable to unaltered 6-I-L-mTyr, whereas with HPLC analysis, no in vivo isomeric conversion of 6-I-L-mTyr was noted.
The differences between in vitro accumulation in the brain and in the pancreas are shown in Table 4 . There was higher accumulation both in the brain and the pan creas with L-isomers than with the D-isomer. 6-I-L-mTyr was noted to have a higher uptake in the brain than 6-I-D-mTyr similar to that found in in vivo biodistribu tion studies. Table 5 shows the percentage effect of control l-mTyr accumulation with inhibitors. Significant inhibition of 6-I-L-mTyr and 4-I-L-mTyr accumulation in the brain was noted with ouabain. NSD-1015 only had an inhibi tory effect on the accumulation of 6-I-L-mTyr in the brain. H22/54 did not have a significant inhibition on the accumulation of radioiodinated mTyr.
In vivo inhibition studies and autoradiography Figures 2A and 2B shows the control uptakes of 6-1-L-mTyr in the midbrain area and in the cerebellum. After preloading with NSD-1015, the uptake in the striatum which is abundant with dopaminergic neurons has de creased (Fig. 2C ). In the thalamus and cerebellum, the significant effect of NSD-1015 pretreatment was not ob served (Fig. 2D ). H22/54 showed no significant effect mentioned above on the same portion (data not shown). These findings coincide with our results in the in vitro studies. 
DISCUSSION
Radioiodination is used extensively as a means of la beling compounds of medical and biologic interest be cause iodine radioisotopes have the advantage of avail ability, low cost, and relatively longer half-lives. In the chloramine-T method, chloramine-T oxidizes the iodine to a reactive iodine species which then labels the com pound of interest. High labeling efficiency and very high specific activity of mTyr can be obtained by this method. In our study, the phenol ring of mTyr provided an ample site for labeling.
To produce a suitable radiotracer by the radioiodin ation method, the radioiodine must be attached in such a way that the physiologic properties of the compound would not be affected. It is also important that the radio iodinated compound is not broken down quickly by gen eral metabolic pathways (Kloss and Leven, 1979) . Oldendorf and Szabo (1976) proposed the presence of specific affinity sites on carrier proteins studded through the plasma of brain capillary endothelial cells that are specific for various amino acids. Betz and Goldstein (1978) confirmed Na+-dependent neutral amino acid transport into isolated brain capillaries. In recent experi ments ouabain, an efficient Na+-K+-ATPase inhibitor, has been used to suppress the Na+-dependent concentra tive uptake of amino acids (Hughes and Lantos, 1989; Sanchez del Pino et aI., 1995) . Because the uptake of 6-I-L-mTyr is inhibited by ouabain, it is transported into the brain by amino acid active transport similar to that of 6-I-L-DOPA (Kawai et aI., 1996) . The transport system could be stereospecific because more of the inhibitory effect of ouabain was noted with 6-I-L-mTyr than with 6-I-D-mTyr, similar to the findings of our previous study (Kawai et aI., 1999) .
This active amino acid transport system is shared by a radioiodinated tyrosine derivative, 3-iodo-a-methyl-L tyrosine (I-L-AMT) which is now being clinically used to study brain tumors (Woesler et aI., 1997) . Like other amino acids with the L-form, 6-I-L-mTyr also has a high accumulation in the brain and is metabolically stable similar to I-L-AMT (Kawai et aI., 1991) . It is the 3-hy droxy moiety of 6-I-L-mTyr which gives it an affinity for DOPA decarboxylase. DOPA decarboxylase may be rate-limiting for mono amine synthesis in the human brain (Gjedde et aI., 1993) . Because DOPA decarboxylase is not regulated in re sponse to the intensity of dopaminergic neurotransmis sion, its activity may be a more precise indicator of the capacity of tissue to synthesize catecholamines (Gjedde et aI., 1991) . 6-I-L-mTyr could occupy the active site of DOPA decarboxylase which is likened to affinity label ing (Wold, 1977) . Being a marker of DOPA decarbox ylase, it could facilitate the quantification of the enzyme. The 3-hydroxy moiety in 6-I-L-mTyr could account for the intracellular interaction with DOPA decarboxylase which could be substantiated by the retention of 6-I-L mTyr in the brain immediately after injection.
NSD-1015, a DOPA decarboxylase inhibitor, is fre quently used in dopamine biosynthesis studies (Sved et aI., 1984; Nissbrandt and Carlsson, 1987) , and it acts in the active site of enzymes. The decrease in uptake of 6-I-L-mTyr upon inhibition of NSD-lOl5 is an indication of the decrease in availability of active sites to be occu pied which could mean less DOPA decarboxylase par ticipating in the dopaminergic presynaptic biosynthesis.
The conversion of L-tyrosine to L-DOPA is catalyzed by the enzyme tyrosine hydroxylase. H22/54 has been used as a tyrosine hydroxylase inhibitor (Maj et aI., 1978; Verhofstad and Jonsson, 1983) . Tyrosine hydrox ylase and DOPA decarboxylase inhibitors have been used to study dopamine biosynthesis (Demarest and Moore, 1980; Duda and Moore, 1985) . The 4-hydroxy group that is present in tyrosine and is lacking in 6-I-L mTyr could explain why there is no effect with H22/54. 6-I-L-mTyr is also noted to have a higher uptake in the pancreas than in the liver. The amino acid is known to accumulate in pancreatic cells and is utilized for synthe sis of proteins and enzymes. Although there is dopamine synthesis and release from nonneuronal exocrine cells of the pancreas (Mezey et aI., 1996) , the minimal inhibition by NSD-lOl5 could not totally account for the very high accumulation of 6-I-L-mTyr in the pancreas. It is more All values are mean ± SD; * P < 0.01.
likely that there is a general incorporation of 6-I-L-mTyr in the pancreas through the amino acid active transport. The L-configuration is responsible for the selectivity of 6-I-L-mTyr in the pancreas and also in the brain. Rapid blood clearance of radioiodinated L-mTyr was also noted especially when compared to 3-I-L-Tyr. The retention of 6-I-L-mTyr in the brain and pancreas delayed the clearance of 6-I-L-mTyr when compared to 6-1-0-mTyr. It is also metabolically stable as proven by the nondeiodination noted (Kawai et aI., 1999) . The in vivo breakdown of radiopharmaceutical results in undesirable biodistribution radioactivity. 6-I-L-mTyr is also rapidly A 101.08 ± 8.08
106.67 ± 8.48 100.85 ± 6.00 101.40 ± 5.69 106.29 ± 8.81 105.54 ± 0.86 excreted by the renal system. The faster the urinary ex cretion the lesser the radiation dose. These results con tribute to the low nonspecific accumulation in nontarget organs.
In summary, we propose that 6-I-L-mTyr, a new ra diopharmaceutical, enters the brain through stereospecif ic amino acid active transport as proven by ouabain in hibition. In the brain, it interacts with DOPA decarbox ylase as confirmed by NSD-IOI5 inhibition; after the interaction it is washed out in the blood and excreted in the urine. It remained metabolically stable as shown by excretion studies. 
